Journal Article

Evidence-based review of antifungal prophylaxis in neutropenic patients with haematological malignancies

Axel Glasmacher and Archibald Grant Prentice

in Journal of Antimicrobial Chemotherapy

Volume 56, issue suppl_1, pages i23-i32
Published in print September 2005 | ISSN: 0305-7453
Published online September 2005 | e-ISSN: 1460-2091 | DOI: http://dx.doi.org/10.1093/jac/dki221
Evidence-based review of antifungal prophylaxis in neutropenic patients with haematological malignancies

More Like This

Show all results sharing these subjects:

  • Medical Oncology
  • Critical Care

GO

Show Summary Details

Preview

Background: There is still no consensus on the efficacy of antifungal prophylaxis in neutropenic patients after more than 50 clinical trials.

Methods: This review evaluates the current evidence from all available meta-analyses of the use of intravenous amphotericin B, fluconazole and itraconazole for this indication.

Results: Four systematic reviews with meta-analysis and one evidence-based review without meta-analysis were evaluated. Efficacy of fluconazole has been shown on short-term follow-up after allogeneic stem cell transplantation but only itraconazole was effective in neutropenic patients with haematological malignancies for prolonged prophylaxis after allogeneic stem cell transplantation. Direct comparison between fluconazole and itraconazole for this indication shows the superiority of itraconazole which was the only drug able to prevent invasive Aspergillus infections in our previously published meta-analysis of 13 trials and 3597 patients. Efficacy of itraconazole correlates closely with its dose; an effect was seen only in clinical trials using at least 400 mg/day oral solution or 200 mg/day intravenous solution. With this dose, invasive fungal infections were reduced by 53% and mortality from invasive fungal infections was reduced by 47% (P < 0.05). Toxicity of itraconazole is rare and usually not severe and drug interactions are easily manageable.

Conclusions: Itraconazole is recommended for antifungal prophylaxis in high-risk neutropenic patients with haematological malignancies or for prolonged prophylaxis after allogeneic stem cell transplantation based on unambiguous evidence of efficacy and low toxicity from clinical trials and systematic reviews.

Keywords: itraconazole; fluconazole; invasive fungal infections; acute leukaemia

Journal Article.  0 words. 

Subjects: Medical Oncology ; Critical Care

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.